Regulatory work attracts AI for an obvious reason: it contains large volumes of documents, repeated structures, distributed evidence, and intense review effort.
It also punishes false confidence.
A fluent draft can omit a qualification, rely on the wrong version, blur a regional difference, or make an unsupported connection sound settled. The right ambition is therefore not “automate regulatory affairs.” It is to design bounded assistance that makes expert work faster to inspect, easier to trace, and harder to lose across handoffs.
The governing principle: context determines risk
In January 2025, the FDA published draft guidance on using AI to support regulatory decision-making for drugs and biological products. Its proposed framework is risk-based: credibility expectations should reflect the model’s context of use and the consequences of an incorrect result. The agency’s guidance page is essential reading for any team considering AI-derived evidence in a submission.
FDA and EMA have also published joint principles for good AI practice in drug development, emphasizing human-centric design, clear context of use, data governance, risk-based assessment, lifecycle management, and understandable information.
The implication is practical: the same model may require very different controls depending on where it sits. Summarizing public guidance for an internal analyst is not equivalent to generating evidence used to support a regulatory decision.
A ladder of regulatory AI use
The safest way to plan the portfolio is to move from bounded, inspectable work toward more consequential use only as evidence and controls mature.
1. Retrieval with provenance
Find the relevant passage in guidance, prior correspondence, controlled procedure, or submission history and return it with source, version, and location. This is foundational. If retrieval is unreliable, downstream drafting only makes the unreliability more articulate.
2. Change detection and comparison
Compare a new publication with prior language. Identify changed obligations, terminology, dates, or scope. The system proposes a difference set; the regulatory owner determines significance.
3. Structured extraction
Pull defined fields from documents into a review table: commitments, deadlines, study identifiers, endpoints, or requested actions. Validation rules and sampling plans should be explicit.
4. Traceable first drafts
Prepare a draft from approved sources, with citations mapped to claims and clear placeholders where evidence is missing. The draft is a starting surface for the expert—not an answer that becomes authoritative because it sounds finished.
5. Bounded quality control
Check cross-references, terminology, defined consistency rules, required sections, or mismatched values. A machine can widen the inspection net; it cannot accept responsibility for scientific or regulatory adequacy.
6. AI supporting regulatory evidence
When model output itself informs evidence or a decision submitted to an agency, the work enters a different assurance category. Context of use, model risk, data fitness, performance, explainability, change control, and documentation require formal treatment aligned with current agency expectations.
What must remain human
Some work can be assisted but not delegated:
- interpretation of ambiguous agency feedback;
- assessment of benefit-risk and scientific uncertainty;
- selection of a regulatory strategy;
- acceptance of residual risk;
- final approval of regulated communications; and
- decisions about what evidence is sufficient for a consequential claim.
This does not mean the AI adds little value. It means value appears around judgment: better preparation, broader retrieval, more systematic comparison, and less avoidable production work.
The control architecture
A credible regulatory workflow should make six controls visible.
Authorized sources. Which repositories, document states, regions, and versions can the system use?
Role-based access. Who can retrieve, draft, review, approve, and change the workflow?
Traceability. Can a reviewer move from each material claim back to the evidence without reconstructing the system’s process?
Validation. How will performance be assessed for the specific task and context—not for a general model benchmark?
Exception handling. What happens when sources conflict, confidence is low, or the case is novel?
Change control. What is re-evaluated when the model, prompt, source corpus, or workflow changes?
The EMA’s reflection paper on AI across the medicinal-product lifecycle similarly frames responsibilities across development and use, including data integrity, governance, and lifecycle considerations.
A sensible first workflow
For many teams, an internal regulatory-intelligence process is a strong starting point. It is frequent, valuable, and inspectable, while the accountable regulatory professional retains interpretation.
A measured pilot might:
- monitor a defined set of authoritative sources;
- classify new items against a controlled taxonomy;
- compare material language with prior guidance and internal procedure;
- generate a cited impact brief;
- route uncertain items to a regulatory owner; and
- track precision, recall, review time, and material corrections.
Only after the mechanism is reliable should the organization extend it toward more consequential drafting or evidence use.
The standard is not perfection. It is controlled usefulness.
Human regulatory work is not error-free, and requiring a model to be perfect is not a serious governance position. The standard is whether the combined system—people, evidence, technology, review, and escalation—is demonstrably fit for its purpose.
AI can strengthen regulatory operations. The winning design will not be the one that removes experts fastest. It will be the one that lets experts see more, inspect sooner, and remain unmistakably accountable.